The sPLA2 inhibition to decrease enzyme release after percutaneous coronary intervention (SPIDER-PCI) trial

Circulation

Volumn 122, Issue 23, 2010, Pages 2411-2418

  Džavík, Vladimír ^a,b,c   Lavi, Shahar ^d   Thorpe, Kevin ^c,e   Yip, Paul M ^a,c   Plante, Sylvain ^c,f   Ing, Douglas ^a,c   Overgaard, Christopher B ^a,c   Osten, Mark D ^a,c   Lan, Julie ^a,c   Robbins, Kim ^c,f   Miner, Steven E ^c,f   Horlick, Eric M ^a,c   Cantor, Warren J ^c,f  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Heart and Stroke Lewar Centre   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

Author keywords

angioplasty; inflammation; myocardial injury; secretory phospholipase A2; sPLA2

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATINE KINASE MB; PLACEBO; SECRETORY PHOSPHOLIPASE A2; TROPONIN I; VARESPLADIB; ACETIC ACID DERIVATIVE; ENZYME INHIBITOR; INDOLE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; MIDDLE AGED; MULTICENTER STUDY; SECRETION;

ACETIC ACIDS; ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY; BIOLOGICAL MARKERS; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PHOSPHOLIPASES A2, SECRETORY;

EID: 78650711954     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.950733     Document Type: Article

References (39)

1. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 1996;94:1528-1536.
2. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J. 2002;23: 869-876.
3. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol. 1991;17:621-626.
4. Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coll Cardiol. 2003;42: 1412-1414.
5. Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, Moliterno DJ, Califf RM, Topol EJ, Ohman EM. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol. 2002;39:1738-1744.
6. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation. 2002; 106:1205-1210.
7. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1406-1411.
8. Fuchs S, Kornowski R, Mehran R, Lansky AJ, Satler LF, Pichard AD, Kent KM, Clark CE, Stone GW, Leon MB. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol. 2000;85:1077-1082.
9. Ricciardi MJ, Davidson CJ, Gubernikoff G, Beohar N, Eckman LJ, Parker MA, Bonow RO. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J. 2003;145:522-528.
10. Okamura A, Ito H, Iwakura K, Kawano S, Kurotobi T, Date M, Inoue K, Ogihara T, Fujii K. Detection and quantification of embolic particles during percutaneous coronary intervention to stable plaque: it correlates to coronary flow dynamics and myocardial damage. Catheter Cardiovasc Interv. 2007;69:425-431.
11. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570-580.
12. Waxman S, Sassower MA, Mittleman MA, Zarich S, Miyamoto A, Manzo KS, Muller JE, Abela GS, Nesto RW. Angioscopic predictors of early adverse outcome after coronary angioplasty in patients with unstable angina and non-Q-wave myocardial infarction. Circulation. 1996;93:2106-2113.
13. van Dijk A, Krijnen PA, Vermond RA, Pronk A, Spreeuwenberg M, Visser FC, Berney R, Paulus WJ, Hack CE, van Milligen FJ, Niessen HW. Inhibition of type 2A secretory phospholipase A2 reduces death of cardiomyocytes in acute myocardial infarction. Apoptosis. 2009;14: 753-763.
14. Fraser H, Hislop C, Christie R, Rick H, Reidy C, Chouinard M, Eacho P, Gould K, Trias J. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/-mice. J Cardiovasc Pharmacol. 2009;53:60-65.
15. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation. 2004;110:674-678.
16. Ma JM, Jackevicius CA, Genus U, Dzavik V. The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention. Can J Cardiol. 2006;22:419-423.
17. Kandzari DE, Labinaz M, Cantor WJ, Madan M, Gallup DS, Hasselblad V, Joseph D, Allen A, Green C, Hidinger KG, Krucoff MW, Christenson RH, Harrington RA, Tcheng JE. Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). Am J Cardiol. 2003;92:660-664.
18. Okmen E, Sanli A, Uyarel H, Dayi S, Tartan Z, Cam N. Effects of glycoprotein IIb/IIIa receptor inhibition with tirofiban on minor myo-cardial damage in angiographically successful percutaneous coronary angioplasty. Cardiology. 2004;102:18-23.
19. Ozdol C, Gulec S, Rahimov U, Atmaca Y, Turhan S, Erol C. Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention. Thromb Res. 2007;119:453-459.
20. Pelliccia F, Pasceri V, Granatelli A, Pristipino C, Speciale G, Roncella A, Cianfrocca C, Mercuro G, Richichi G. Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris. Am J Cardiol. 2006;98:1461-1463.
21. Wang FW, Osman A, Otero J, Stouffer GA, Waxman S, Afzal A, Anzuini A, Uretsky BF. Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation. 2003;107:2914-2919.
22. R Development Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
23. Pinheiro J, Bates D. Mixed-Effects Models in S and S-PLUS: Statistics and Computing Series. New York, NY: Springer-Verlag; 2004.
24. Bates D, Sarkar D. lme4: linear mixed-effects models using S4 classes, 2008. Version 0.999375-28. Available at: http://CRAN.R-project.org/package = lme4, R package. Accessed July 19, 2010.
25. Baayen R, Davidson D, Bates D. Mixed-effects modeling with crossed random effects for subjects and items. J Mem Lang. 2008;59:390-412.
26. Rosenson RS, Hislop C, McConnell D, Elliott M, Stasiv Y, Wang N, Waters DD. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet. 2009;373: 649-658.
27. Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, Banning AP. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation. 2005; 111:1027-1032. (Pubitemid 40354521)
28. Bolognese L, Ducci K, Angioli P, Falsini G, Liistro F, Baldassarre S, Burali A. Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2004;110:1592-1597.
29. Angelini A, Rubartelli P, Mistrorigo F, Della Barbera M, Abbadessa F, Vischi M, Thiene G, Chierchia S. Distal protection with a filter device during coronary stenting in patients with stable and unstable angina. Circulation. 2004;110:515-521.
30. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P. Phospholipase A(2) in vascular disease. Circ Res. 2001;89:298-304.
31. Tietge UJ, Pratico D, Ding T, Funk CD, Hildebrand RB, Van Berkel T, Van Eck M. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J Lipid Res. 2005;46:1604-1614.
32. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, Huart V, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekholdt SM. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol. 2007;27:1177-1183.
33. Liu PY, Li YH, Tsai WC, Chao TH, Tsai LM, Wu HL, Chen JH. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J. 2003;24: 1824-1832.
34. Nijmeijer R, Lagrand WK, Baidoshvili A, Lubbers YT, Hermens WT, Meijer CJ, Visser CA, Hack CE, Niessen HW. Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans. Cardiovasc Res. 2002;53:138-146.
35. Nijmeijer R, Willemsen M, Meijer CJ, Visser CA, Verheijen RH, Gottlieb RA, Hack CE, Niessen HW. Type II secretory phospholipase A2 binds to ischemic flip-flopped cardiomyocytes and subsequently induces cell death. Am J Physiol Heart Circ Physiol. 2003;285: H2218-H2224.
36. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22:1649-1654.
37. Kell PJ, Creer MH, Crown KN, Wirsig K, McHowat J. Inhibition of platelet-activating factor (PAF) acetylhydrolase by methyl arachidonyl fluorophosphonate potentiates PAF synthesis in thrombin-stimulated human coronary artery endothelial cells. J Pharmacol Exp Ther. 2003; 307:1163-1170.
38. Rastogi P, Beckett CS, McHowat J. Prostaglandin production in human coronary artery endothelial cells is modulated differentially by selective phospholipase A(2) inhibitors. Prostaglandins Leukot Essent Fatty Acids. 2007;76:205-212. 39.
39. Snyder DW, Bach NJ, Dillard RD, Draheim SE, Carlson DG, Fox N, Roehm NW, Armstrong CT, Chang CH, Hartley LW, Johnson LM, Roman CR, Smith AC, Song M, Fleisch JH. Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: a new class of anti-inflammatory drugs, SPI. J Pharmacol Exp Ther. 1999;288:1117-1124.